Curevac N.V. (NQ: CVAC )
7.360 -0.060 (-0.81%) Streaming Delayed Price Updated: 4:00 PM EDT, Sep 26, 2023 Add to My Watchlist
All News about Curevac N.V.
CureVac: Second-Generation COVID-19 Vaccine Candidate, CV2CoV, Demonstrates High Immunogenicity Against Virus Variants in Preclinical Study
May 13, 2021
- Second-generation lead COVID-19 vaccine candidate, CV2CoV, developed in collaboration by CureVac and GSK - CV2CoV mRNA shows high levels of antigen production in rat model - Fast onset of strong...
CureVac Swiss AG Initiates Rolling Submission Process for mRNA-based COVID-19 Vaccine Candidate, CVnCoV, with Swissmedic
April 19, 2021
- Rolling submission to accelerate time to marketing authorization of CVnCoV in Switzerland - Review process started with submission of first CVnCoV data package TÜBINGEN, GERMANY and BOSTON, MA /...
CureVac Announces Financial Results and Business Updates for the Fourth Quarter and Full-Year of 2020
April 15, 2021
- COVID-19 vaccine candidate: CVnCoV in final stage of clinical development and believed to be well on track to provide data for conditional approval based on EMA rolling submission - Pivotal Phase...
CureVac to Report Fourth Quarter and Full-Year 2020 Financial Results and Business Updates on April 15, 2021
April 09, 2021
TÜBINGEN, GERMANY and BOSTON, MA / ACCESSWIRE / April 9, 2021 / CureVac N.V. (Nasdaq:CVAC), a biopharmaceutical company developing a new class of transformative medicines based on messenger ribonucleic...